Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Filgrastim secondary prophylaxis versus conservative management for chemotherapy-induced neutropenia in breast cancer
ISRCTN89698860Phase 3Completed
- Sponsor
- Anglo Celtic Cooperative Oncology Group
- Start
- Oct 2001
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, open-label trial of filgrastim in breast cancer (2 arms), sponsored by Anglo Celtic Cooperative Oncology Group. Started Oct 2001; status: completed.
02
Drugs
filgrastim
03
Conditions
breast cancer
Beyond the preview
Go deeper on ISRCTN89698860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN89698860.